Get the Daily Brief
Latest Biotech News
FDA Vaccine Policy Turmoil: RFK Jr. Faces Senate Scrutiny Amid CDC Staff Exodus
U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. confronted rigorous questioning and criticism during a Senate Finance Committee hearing focused on vaccine policy upheaval and...
Thermo Fisher Completes $4B Solventum Filtration Deal, Expands Life Sciences Segment
Thermo Fisher Scientific finalized its acquisition of Solventum's purification and filtration business for approximately $4.0 billion in cash, integrating it into the Life Sciences Solutions...
Octave Bioscience Raises $35.6M Series C Plus $15.5M Loan for Neurology Diagnostics
Octave Bioscience secured $35.6 million in Series C funding alongside a $15.5 million non-dilutive term loan from Silicon Valley Bank to advance its proteomic diagnostic tests. The company’s MSDA...
FDA Increases Transparency by Publishing Complete Response Letters for Drug Rejections
The Food and Drug Administration committed to enhanced transparency by releasing complete response letters (CRLs) to drugmakers shortly after issuance, including 89 previously undisclosed letters...
Atlas Venture Raises $400M Opportunity Fund to Support Portfolio Biotech Companies
Atlas Venture closed a $400 million Opportunity Fund aimed at supporting follow-on financing for its existing portfolio companies amid ongoing fundraising challenges in the biotech sector. The...
Treeline Biosciences Emerges with $1B Raised and Multiple Cancer Drug Candidates
Stealth-mode biotech Treeline Biosciences has revealed its first cancer drug candidates entering clinical trials and announced an additional $200 million in funding, accumulating over $1.1 billion...
BioNTech’s HER2 ADC Outperforms Roche’s Kadcyla in Phase 3 Breast Cancer Trial in China
BioNTech announced that its HER2-targeting antibody-drug conjugate achieved superior results over Roche's Kadcyla in a Phase 3 clinical trial conducted in China involving hard-to-treat breast...
Radiance Biopharma Signs $1.165B Deal for c-MET/EGFR Bispecific Nanobody ADC
Radiance Biopharma acquired global rights outside certain Asian markets for a bispecific nanobody antibody-drug conjugate targeting c-MET and EGFR to treat solid tumors, in a deal potentially...
Mechanism of Anemia in Bone Metastasis Unveiled by Princeton Researchers
Researchers at Princeton University and Rutgers Cancer Institute elucidated that anemia in patients with bone metastases stems from tumor cells hijacking specialized iron-transporting erythroblast...
CRISPR-Cas9 Functions as a Bacterial Defense Guardian Beyond Genome Editing
Research has uncovered a novel role of the CRISPR-Cas9 system, revealing that Cas9 acts as a guardian in bacterial immunity. Initially discovered in the early 2000s as a mechanism bacteria use to...
Atlas Venture Raises $400 Million 'Opportunity Fund' to Support Existing Biotech Startups
Atlas Venture has announced the closing of a $400 million Opportunity Fund III, aimed at providing follow-up financing to biotechs in its existing portfolio. This fund targets promising companies...
Treeline Biosciences Emerges with $1.1 Billion Raised and Three Cancer Programs in Clinic
After years under the radar, Treeline Biosciences disclosed its first clinical candidates targeting various cancers and announced a $200 million extension of its Series A funding, lifting total...
FDA Implements New Pathway for Ultra-Rare Disease Drug Approvals
The U.S. Food and Drug Administration unveiled the Rare Disease Evidence Principles (RDEP), a coordinated review program between its drug and biologics centers to facilitate expedited approval of...
FDA Commits to Publishing Complete Drug Rejection Letters to Enhance Transparency
FDA Commissioner Marty Makary announced a new policy to publicly release redacted complete response letters (CRLs) simultaneously with drug sponsors receiving them. This landmark decision aims to...
Charm Therapeutics Secures $80 Million to Advance Menin Inhibitor for Leukemia
London-based Charm Therapeutics completed an $80 million Series B funding round led by New Enterprise Associates and DR One to develop its next-generation menin inhibitor targeting acute myeloid...
Novel High-Throughput Antibody Platform Accelerates Therapeutic Discovery
Scientists at the University of Illinois Urbana-Champaign revealed oPool+ display, a high-throughput technology capable of synthesizing and assessing hundreds of antibodies in parallel against...
Amgen Invests Over $600 Million in U.S. Center for Science and Innovation
Amgen announced a $600 million investment to establish a state-of-the-art scientific research and development center at their global headquarters in Thousand Oaks, California. The facility aims to...
Novartis and Argo Biopharma Expand $9 Billion Collaboration on RNAi Therapeutics
Novartis has deepened its partnership with Shanghai-based Argo Biopharma, signing a new deal valued at up to $5.2 billion, including $160 million upfront payments and substantial milestones. This...
Medical Community Criticizes Florida's Plan to End Vaccine Mandates
Florida's decision to remove all vaccine mandates has drawn sharp criticism from healthcare experts and organizations who warn it threatens public health by increasing the risk of preventable...
Charm Therapeutics Raises $80 Million to Advance Menin Inhibitor for Leukemia
London-based Charm Therapeutics secured $80 million in a Series B funding round co-led by New Enterprise Associates and DR One, aimed at advancing its menin inhibitor drug candidate targeting...